Pharoah,P.D. et al. (2008) Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med., 358, 2796-2803.
Couch,F.J., Nathanson,K.L. and Offit,K. (2014) Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention. Science, 343, 1466-1470.
Michailidou,K. et al. (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genet., 45, 353-361.
Spurdle,A.B. et al. (2012) ENIGMA-Evidence-Based Network for the Interpretation of Germline Mutant Alleles: An International Initiative to Evaluate Risk and Clinical Significance Associated with Sequence Variation in BRCA1 and BRCA2 Genes. Hum Mutat, 33, 2-7.
Southey,M.C. et al. (2013) COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Res., 15, 402.
Antoniou,A.C. et al. (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet, 45, 425-431.
MacInnis,R.J. et al. (2013) Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. Br. J. Cancer, 109, 1296-1301.
Riley,B.D. et al. (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns., 21, 151-161.
Smith,R.A. et al. (2014) Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin., 64, 30-51.
Kurian,A.W. et al. (2014) Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol., 32, 2001-2009.
Eijzenga,W. et al. (2014) Specific psychosocial issues of individuals undergoing genetic counseling for cancer – a literature review. J Genet Couns., 23, 133-146.
Power,T.E. et al. (2011) Distress and psychosocial needs of a heterogeneous high risk familial cancer population. J Genet Couns., 20, 249-269.
Spurdle,A.B. et al. (2012) BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet, 49, 525-532.
Lee,S.B. et al. (2001) Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res., 61, 8062-8067.
Easton,D. et al. (2004) CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet, 74, 1175-1182.
Vroling,B. et al. (2012) NucleaRDB: information system for nuclear receptors. Nucleic Acids Res., 40, D377-D380.
Guidugli,L. et al. (2013) A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity. Cancer Res., 73, 265-275.
Spurdle,A.B. (2010) Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. Curr. Opin. Genet Dev., 20, 315-323.
Plon,S.E. et al. (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat., 29, 1282-1291.
Lindor,N.M. et al. (2012) A Review of a Multifactorial Probability-Based Model for Classification of BRCA1 and BRCA2 Variants of Uncertain Significance (VUS). Hum Mutat, 33, 8-21.
Easton,D.F. et al. (2007) A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am. J. Hum. Genet., 81, 873-883.
Thompson,B.A. et al. (2014) Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet., 46, 107-115.
Damiola,F. et al. (2014) Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res., 16, R58.
Antoniou,A.C. and Easton,D.F. (2003) Polygenic inheritance of breast cancer: Implications for design of association studies. Genet. Epidemiol., 25, 190-202.
Tavtigian,S.V. et al. (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J. Med. Genet., 43, 295-305.
Hicks,S. et al. (2011) Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed. Hum Mutat., 32, 661-668.
Akbari,M.R. et al. (2011) Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes. J Med Genet, 48, 783-786.
Kircher,M. et al. (2014) A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet., 46, 310-315.
Kilpivaara,O. et al. (2004) CHEK2 variant 1157T may be associated with increased breast cancer risk. Int. J. Cancer, 111, 543-547.
Goldgar,D.E. et al. (2011) Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res., 13, R73.
Rahman,N. et al. (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genet., 39, 165-167.
Antoniou,A.C. et al. (2014) Breast-cancer risk in families with mutations in PALB2. N. Engl. J Med., 371, 497-506.
Mavaddat,N. et al. (2010) Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res., 12.
Roy,R., Chun,J. and Powell,S.N. (2012) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature Reviews Cancer, 12, 68-78.
Millot,G.A. et al. (2012) A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat, 33, 1526-1537.
Bouwman,P. et al. (2013) A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants. Cancer Discovery, 3, 1142-1155.
Guidugli,L. et al. (2014) Functional Assays for Analysis of Variants of Uncertain Significance in BRCA2. Hum Mutat., 35, 151-164.
Balmana,J. et al. (2011) Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov., 1, 29-34.
Jasin,M. and Rothstein,R. (2013) Repair of strand breaks by homologous recombination. Cold Spring Harb. Perspect. Biol., 5, a012740.
Mimitou,E.P. and Symington,L.S. (2009) Nucleases and helicases take center stage in homologous recombination. Trends Biochem. Sci., 34, 264-272.
Suwaki,N., Klare,K. and Tarsounas,M. (2011) RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin. Cell Dev. Biol., 22, 898-905.
Spurdle,A.B. et al. (2008) Prediction and assessment of splicing alterations: implications for clinical testing. Hum. Mutat., 29, 1304-1313.
Vreeswijk,M.P.G. et al. (2009) Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. Hum. Mutat., 30, 107-114.
Vreeswijk,M.P. and van der Klift,H.M. (2012) Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders. Methods Mol. Biol., 867, 49-63.
de Garibay,G.R. et al. (2014) Capillary Electrophoresis Analysis of Conventional Splicing Assays: IARC Analytical and Clinical Classification of 31 BRCA2 Genetic Variants. Hum Mutat, 35, 53-57.
Thomassen,M. et al. (2012) Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Res Treatm, 132, 1009-1023.
Dosil,V. et al. (2010) Alternative Splicing and Molecular Characterization of Splice Site Variants: BRCA1 c.591C > T as a Case Study. Clin Chem, 56, 53-61.
Whiley,P.J. et al. (2014) Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing. Clin Chem., 60, 341-352.
Mercer,T.R. et al. (2011) Targeted RNA sequencing reveals the deep complexity of the human transcriptome. Nat Biotechnol., 30, 99-104.
Colombo,M. et al. (2014) Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. Hum Mol. Genet., 23, 3666-3680.
Walker,L.C. et al. (2013) Evaluation of a 5-tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: inter-reviewer variability and promotion of minimum reporting guidelines. Hum Mutat., 34, 1424-1431.
Gaildrat,P. et al. (2010) Use of splicing reporter minigene assay to evaluate the effect on splicing of unclassified genetic variants. Methods Mol. Biol., 653, 249-257.
Whiley,P.J. et al. (2010) Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts. Bmc Medical Genetics, 11.
Park,D.J. et al. (2012) Rare Mutations in XRCC2 Increase the Risk of Breast Cancer. Am J Hum Genet, 90, 734-739.
Hilbers,F.S. et al. (2012) Rare variants in XRCC2 as breast cancer susceptibility alleles. J Med Genet, 49, 618-620.
Puget,N., Knowlton,M. and Scully,R. (2005) Molecular analysis of sister chromatid recombination in mammalian cells. DNA Repair (Amst)., 4, 149-161.
Hurov,K.E., Cotta-Ramusino,C. and Elledge,S.J. (2010) A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability. Genes Dev., 24, 1939-1950.
Rantakari,P. et al. (2010) Inactivation of Palb2 gene leads to mesoderm differentiation defect and early embryonic lethality in mice. Hum. Mol. Genet., 19, 3021-3029.
Kuznetsov,S.G. et al. (2009) Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice. Cancer Res., 69, 863-872.
Zhang,F. et al. (2009) PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response. Curr. Biol., 19, 524-529.
Badie,S. et al. (2009) RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation. J Cell Biol., 185, 587-600.
Huzarski,T. et al. (2013) Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer. J Clin Oncol, 31, 3191-+.
Elwyn,G., Gray,J. and Clarke,A. (2000) Shared decision making and non-directiveness in genetic counselling. J Med Genet., 37, 135-138.
Stuckey,A. et al. (2014) Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals. Am J Clin Oncol., Apr 5. [Epub ahead of print].
Beitsch,P.D. and Whitworth,P.W. (2014) Can Breast Surgeons Provide Breast Cancer Genetic Testing? An American Society of Breast Surgeons Survey. Ann Surg. Oncol.
Hamilton,J.G., Lobel,M. and Moyer,A. (2009) Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol., 28, 510-518.
Vos,J. et al. (2012) Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees’ perception, the medical impact by the pathogenic or uninformative BRCA1/2-result. Psychooncology., 21, 29-42.
Bredart,A. et al. (2013) Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer. Br. J Cancer., %19;108, 1012-1020.
Rosenberg,S.M. et al. (2013) Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern. Med., 159, 373-381.
van,D.S. et al. (2009) The Distress Thermometer assessed in women at risk of developing hereditary breast cancer. Psychooncology., 18, 1080-1087.
Tabachnick,B.G. and Fidell,L.S. (2007) Experimental Designs Using ANOVA. Cengage Learning, Belmont, CA.
Johansson,I., Ringner,M. and Hedenfalk,I. (2013) The Landscape of Candidate Driver Genes Differs between Male and Female Breast Cancer. Plos One, 8.
Evans,D.G.R. et al. (2012) Assessing Individual Breast Cancer Risk within the UK National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention. Cancer Prevention Research, 5, 943-951.
Finch,A.P.M. et al. (2014) Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. J Clin Oncol, 32, 1547-1U43.
Evans,D.G.R. et al. (2009) Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet, 46, 254-258.
Nazarali,S.A. and Narod,S.A. (2014) Tamoxifen for women at high risk of breast cancer. Breast Cancer (Dove. Med Press)., 6, 29-36.
Paci,E. et al. (2014) European Breast Cancer Service Screening Outcomes: A First Balance Sheet of the Benefits and Harms. Cancer Epidemiol Biomarkers Prev., 23, 1159-1163.
Independent UK Panel on Breast Cancer Screening et al. (2012) The benefits and harms of breast cancer screening: an independent review. Lancet, 380, 1778-1786.
Hall,P. and Easton,D. (2013) Breast cancer screening: time to target women at risk. Br. J Cancer., 108, 2202-2204.
Kriege,M. et al. (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N. Engl. J. Med., 351, 427-437.
Leach,M.O. et al. (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet, 365, 1769-1778.
Fokkema,I.F. et al. (2011) LOVD v.2.0: the next generation in gene variant databases. Hum Mutat., 32, 557-563.
Wu,M.C. et al. (2011) Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet., 89, 82-93.
Tyrer,J.P. et al. (2013) The admixture maximum likelihood test to test for association between rare variants and disease phenotypes. BMC Bioinformatics., 14, 177.
Schackmann,E.A. et al. (2013) Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Fam. Cancer., 12, 65-73.
Easton,D. et al. (1993) Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am. J. Hum. Genet., 52, 678-701.